|Bid||6.83 x 800|
|Ask||9.73 x 800|
|Day's Range||7.20 - 7.64|
|52 Week Range||7.05 - 17.19|
|Beta (3Y Monthly)||1.71|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.43|
AUSTIN, Texas, Nov. 16, 2018 -- Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, announced today that Rob Neville, Savara’s Chief Executive Officer, will participate.
Completed Enrollment in Two Clinical Studies of Molgradex: IMPALA, a Pivotal Phase 3 Study and OPTIMA, a Phase 2a StudyIMPALA Top Line Results Expected Q2 2019OPTIMA Interim.
AUSTIN, Texas, Nov. 01, 2018 -- Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced it will release its third quarter 2018 financial results on.
Savara remains on track to report interim results from the OPTIMA study in the fourth quarter of 2018, with top line results expected in the second quarter of 2019. Molgradex is also being investigated in a global pivotal Phase 3 clinical study, called IMPALA, for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP).
Today I will be providing a simple run through of a valuation method used to estimate the attractiveness of Savara Inc (NASDAQ:SVRA) as an investment opportunity by estimating the company’s Read More...
Molgradex is also being investigated in an open-label, multicenter, safety extension study, called IMPALA-X, to determine the long-term safety and utilization of Molgradex in patients with aPAP. IMPALA-X offers patients the opportunity to continue treatment with Molgradex for up to three years after completion of the pivotal Phase 3 IMPALA study.
Savara Inc. (SVRA), an orphan lung disease company, today provided patient enrollment updates for its Molgradex pivotal Phase 3 clinical study, IMPALA, for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP), as well as its Molgradex Phase 2a clinical study, OPTIMA, for the treatment of nontuberculous mycobacterial (NTM) lung infection, both of which were guided to complete enrollment by the end of Q3 2018. Patient enrollment in the IMPALA study is currently at 129 patients out of a total target of 135 patients, with sufficient patients in screening to complete enrollment within the coming weeks and topline data still anticipated in Q2 2019.
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Savara, Inc. (NASDAQ: SVRA ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 5:30 PM Eastern Time. To listen ...
Howard Lubert, President of the Keiretsu Forum Mid-Atlantic, a global angel investor network, joined Rob Neville CEO of Savara on Monday, June 23, 2018, to ring the Opening Bell at Nasdaq MarketSite. Philadelphia, Pennsylvania--(Newsfile Corp. - July 26, 2018) - Howard Lubert, President of the Keiretsu Forum Mid-Atlantic, a global angel investor network, joined Rob Neville CEO of Savara, (Nasdaq: SVRA), an orphan lung disease company, as they rang the Opening Bell at the ...
AUSTIN, TX--(Marketwired - May 01, 2018) - Savara Inc. (SVRA), an orphan lung disease company, today announced it will release its first quarter 2018 financial results on Wednesday, May 9, 2018. Savara management will also host a conference call for investors beginning at 5:30 p.m. ET on Wednesday, May 9, 2018 to discuss its first quarter 2018 financial results and to provide a business update. Shareholders and other interested parties may access the conference call by dialing (855) 239-3120 from the U.S., (855) 669-9657 from Canada, and (412) 542-4127 from elsewhere outside the U.S. and requesting the Savara Inc. call.